GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nextbiomedical Co Ltd (XKRX:389650) » Definitions » Minority Interest

Nextbiomedical Co (XKRX:389650) Minority Interest : ₩0.00 Mil (As of Mar. 2025)


View and export this data going back to 2024. Start your Free Trial

What is Nextbiomedical Co Minority Interest?

Minority interest is the carrying amount of the equity interests owned by non-controlling shareholders, partners, or other equity holders in one or more of the entities included in the reporting entity's consolidated financial statements.

Nextbiomedical Co's minority interest for the quarter that ended in Mar. 2025 was ₩0.00 Mil.


Nextbiomedical Co Minority Interest Historical Data

The historical data trend for Nextbiomedical Co's Minority Interest can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nextbiomedical Co Minority Interest Chart

Nextbiomedical Co Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24
Minority Interest
- - - - -

Nextbiomedical Co Quarterly Data
Dec20 Dec21 Dec22 Mar23 Sep23 Dec23 Mar24 Sep24 Dec24 Mar25
Minority Interest Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Nextbiomedical Co Minority Interest Calculation

Minority interest is the carrying amount of the equity interests owned by non-controlling shareholders, partners, or other equity holders in one or more of the entities included in the reporting entity's consolidated financial statements.


Nextbiomedical Co Business Description

Traded in Other Exchanges
N/A
Address
Venture-ro, No. 6, 100 beongil, Yeonsu-gu, Incheon, KOR
Nextbiomedical Co Ltd is an bio-solution company. The company develops and commercializes therapeutic agents for treating diseases based on polymer and drug delivery system technology. The company has developed products that include endoscopic hemostatic agents, vascular embolic microspheres, and others.

Nextbiomedical Co Headlines

No Headlines